Anagenics Limited · ASX:AN1
Anagenics — Cellmid — Pharma R&D Partnering World Asia conference 2010
12 slides from Anagenics's conference presentation, Mar 19, 2010
Slide 1: ASX Announcement: Validated Cancer Marker Presentation
ASX ANNOUNCEMENT VALIDATED CANCER MARKER PRESENTATION Sydney, 19 March 2010: Darren Jones head of product development of Cellmid Limited presented at the Pharma R&D Partnering World Asia conference. A full copy of his presentation is attached. For further information visit www.cellmid.com.au or cont
Slide 2: Midkine: A validated marker for early diagnosis of cancer
Midkine A validated marker for the early diagnosis and disease management of cancer March 2010 1
Slide 3: Cellmid business strategy: own the target (midkine)
Cellmid (ASX:CDY) Cellmid business strategy: “own the target” (midkine) Cellmid owns the most comprehensive global patent portfolio around midkine (MK) • 19 patent families, ~70 patents • MK to detecting early cancers, use of anti-MK agents to treat autoimmune & inflammatory diseases and cancers, us
Slide 4: Midkine
Midkine Small protein (13kD, 121 aas) with two domains Growth factor prominent in embryogenesis but largely undetectable in adults Actions: inhibits apoptosis, modulates angiogenesis, promotes cell growth and drives inflammatory cell migration Has an important role in cancer progression, onset of in
Slide 5: Midkine Product Development
Midkine Product Development 4
Slide 6: Midkine for cancer diagnosis
Midkine for cancer diagnosis Serum midkine is elevated in many different types of carcinoma Normal: n = 135, mean = 0.15 (100% range 0.00-0.50). Assay cut-off, 0.50ng/mL Esophageal ** n = 18, 0.71 (0.47-1.28) Gastric ** n = 30, 0.77 (0.58-1.24) Duodenal * n = 2, 0.71 (0.46-0.96) Colon ** n = 25, 0.9
Slide 7: Midkine for breast cancer detection
Midkine for breast cancer detection Midkine plasma concentration in combination with conventional markers greatly enhances disease detection over conventional markers alone Combination of tumor markers No. of cases (%) 1. CA15-3/CEA/NCCST-439 positive 44 (29.9%) 2. Midkine/CA15-3/CEA positive 66 (44
Slide 8: Midkine for early detection of esophageal cancer
Midkine for early detection of esophageal cancer Midkine serum concentration in 60 Stage I superficial esophageal squamous cell carcinoma patients greatly enhances disease detection over conventional markers % 60 50 50 40 30 20 20 13 8 8 10 0 Midkine p53 Ab Midkine CEA SCC CYFRA Using serum MK cut-o
Slide 9: Midkine for disease staging
Midkine for disease staging Midkine serum concentration in 220 patients with staged neuroblastoma 6 Stage 4S (91.7%; n=12) Stage 4 4 (83.9%; n=56) Stage 3 (70.0%; n=40) Stage 2 2 (59.0%; n=39) Stage 1 (38.4%; n=73) P<0.0001 Normal 0 (0.0%; n=17) 10 102 103 104 105 106 10 100 1000 10000 100000 100000
Slide 10: Midkine as prognostic
Midkine as prognostic Five year survival curves of 93 patients with esophageal squamous cell carcinoma 100 S-MK<300pg/ml (n=36) ) % 80 ( e t a 60 R l a 40 v i v S-MK>300pg/ml (n=57) r u 20 S P<0.001 0 0 10 20 30 40 50 60 Months Shimada et al Cancer Sci 2003
Slide 11: Current and future work
Current and future work Fully validated ELISA for detecting MK nearing completion Large comparative studies of blood MK with conventional markers Strategy: license diagnostic use of MK for cancer by indication • Exclusive and non-exclusive license opportunities are available in several cancer indica
Slide 12: Thank you
Thank you CELLMID LIMITED 40 King Street Sydney NSW 2000 AUSTRALIA T: +61 2 9299 0311 F: +61 2 9299 2128 www.cellmid.com.au Darren Jones Head of Product Development jones@cellmid.com.au 11
Cellmid — Pharma R&D Partnering World Asia conference 2010 on 6ix